BLOSSOMNCT05835310
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Oct 1, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 25 versions: 24 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 103 → 111 locations
Notable Eligibility criteria expanded, about 17 words Show 4 more changesShow less
- Primary endpoints: details revised at 1 of 5 entries
- Secondary endpoints: details revised at 2 of 11 entries
- Site details revised at 3 of 103 sites
- Study description expanded, about 5 words
- Minor Trial sites expanded: 100 → 103 locationsv24
- Minor Study sites: 99 to 100v23
- Notable Eligibility criteria expanded, about 108 words
- Secondary endpoints: details revised at 1 of 11 entries
Show 19 earlier versionsHide 19 earlier versions
- Minor Study sites: 98 to 99v20
- Minor Study sites: 97 to 98v19
- Minor Study sites: 96 to 97v18
- Notable Eligibility criteria shortened, about 24 words
- Study sites: 94 to 96
- Secondary endpoints: 9 to 11
- Minor Study sites: 92 to 94v16
Notable Eligibility criteria expanded, about 8 wordsv15 Show 5 more changesShow less
- Primary endpoints: 7 to 5
- Study completion date: Mar 12, 2030 to Jan 9, 2030
- Secondary endpoints revised (9)
- Study description revised
- Site details revised at 3 of 92 sites
- Minor Site details revised at 4 of 92 sitesv14
- Minor Primary completion date: Jul 25, 2029 to Oct 5, 2028
- Site details revised at 3 of 92 sites
- Minor Site details revised at 3 of 92 sitesv12
- Minor Site details revised at 2 of 92 sitesv11
- Notable Trial status: Active, Not Recruiting to Recruiting
- Study sites: 87 to 92
- Minor Study sites: 88 to 87v9
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 92 to 88
- Minor Site details revised at 10 of 92 sitesv7
- Minor Site details revised at 2 of 92 sitesv6
- Minor Site details revised at 13 of 92 sitesv5
- Minor Study sites: 81 to 92
- Study completion date: May 21, 2030 to Mar 12, 2030
Notable Eligibility criteria expanded, about 51 wordsv3 Show 4 more changesShow less
- Study sites: 77 to 81
- Study completion date: Jan 15, 2030 to May 21, 2030
- Secondary endpoints: 8 to 9
- Study description expanded, about 8 words
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Start date changed from estimate of Jun 21, 2023 to Mar 14, 2024
- Study sites: 0 to 77
- Primary completion date: Oct 9, 2029 to Jul 25, 2029
- Study completion date: Oct 9, 2029 to Jan 15, 2030
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Randomized participants will receive anifrolumab via intravenous (IV) infusion every 4 weeks
Randomized participants will receive matching placebo via IV infusion
Biologicals: Anifrolumab
Drugs: Placebo
Sites
111 sites in 18 countries
United States 23, Japan 13, China 11, Brazil 7, Spain 7, United Kingdom 7, Italy 6, France 5, Mexico 5, Argentina 4, South Africa 4, Turkey (Türkiye) 4, Canada 3, Germany 3, Poland 3, Portugal 3, Colombia 2, Taiwan 1